Veradermics, Incorporated (MANE)
| Market Cap | 4.70B |
| Revenue (ttm) | n/a |
| Net Income | -98.80M |
| EPS | -15.84 |
| Shares Out | 41.78M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 220,307 |
| Open | 110.19 |
| Previous Close | 111.54 |
| Day's Range | 110.19 - 114.22 |
| 52-Week Range | 32.00 - 131.24 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 163.50 (+45.39%) |
| Earnings Date | Aug 11, 2026 |
About MANE
Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in the development of VDMN, a dissolvable microarray patch technology for immunotherapy of common warts; VDAA for the treatment of alopecia areata; and VDM... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for MANE stock is "Strong Buy." The 12-month stock price target is $163.5, which is an increase of 45.39% from the latest price.
News
Veradermics presents data from subgroup analysis of Phase 2/3 VDPHL01 study
Veradermics (MANE) announced the presentation of data from the Phase 2/3 Study ‘302’ of VDPHL01 in male patients with mild-to-moderate pattern hair loss. The subgroup analysis data were shared in…
Veradermics Announces Presentations of Data from a Subgroup Analysis of Phase 2/3 Study ‘302' in Males with Pattern Hair Loss at 2026 American Academy of Dermatology Innovation Academy
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair ...
Veradermics price target raised to $160 from $135 at Citi
Citi raised the firm’s price target on Veradermics (MANE) to $160 from $135 and keeps a Buy rating on the shares. The firm says the company’s Study 207 showed “robust”…
B. Riley Analyst Initiates Coverage of Veradermics Stock (MANE) With a Buy Rating
Veradermics stock soared on Wednesday after analyst Mayank Mamtani initiated coverage of the company’s shares.
Veradermics Transcript: Study result
Study 207 demonstrated that VDPHL01, an oral extended-release minoxidil, produced rapid, robust, and visible hair regrowth in women with pattern hair loss, with nearly 90% reporting improvement and a favorable safety profile. The results position VDPHL01 as a potential first FDA-approved oral treatment for this large, underserved population.
Veradermics Press release: Study result
Veradermics issued a press release on July 15, 2026, disclosing material business information to investors.
Veradermics Slides: Study result
Veradermics has posted slides in relation to its latest quarterly earnings report, which was published on July 15, 2026.
Veradermics announces results from Phase 2 trial of VDPHL01
Veradermics (MANE) announced positive topline results from its open-label Phase 2 clinical trial evaluating VDPHL01, a proprietary extended-release oral minoxidil formulation, in females with mild-to-...
Veradermics' Oral VDPHL01 Delivers Positive Study ‘207' Phase 2 Clinical Trial Results in Female Pattern Hair Loss Ahead of Upcoming Phase 2/3 Study ‘306' Readout
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair ...
Veradermics initiated with a Buy at B. Riley
B. Riley initiated coverage of Veradermics (MANE) with a Buy rating and $170 price target The firm views the company’s lead asset VDPHL01, an extended-release oral minoxidil, as having a…
Veradermics to Hold Conference Call to Discuss Study ‘207' Phase 2 Clinical Trial Results of VDPHL01 in Females with Mild-to-Moderate Pattern Hair Loss
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair ...
Veradermics price target raised to $182 from $138 at Jefferies
Jefferies raised the firm’s price target on Veradermics (MANE) to $182 from $138 and keeps a Buy rating on the shares. The firm expects VDPHL01 Phase 2 female pattern hair…
Biotech ETF Index Surges 10% After Rebalance
After a sweeping semi-annual rebalance, the biotech index underlying the ALPS Medical Breakthroughs ETF (SBIO) gained over 10% in just six trading days beginning June 18. Key Takeaways: SBIO's underly...
Veradermics initiated with an Outperform at LifeSci Capital
LifeSci Capital analyst Rami Katkhuda initiated coverage of Veradermics (MANE) with an Outperform rating and $135 price target
Veradermics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Strong phase II/III results for an extended-release oral minoxidil tablet show rapid, consistent hair growth and high tolerability in male pattern hair loss, with female trials underway. Market research reveals high unmet need and willingness to adopt, especially among women.
Veradermics Transcript: Jefferies Global Healthcare Conference 2026
Pattern hair loss affects 80 million in the U.S., with significant unmet need and dissatisfaction with current treatments. Recent clinical trial data show strong efficacy and safety for a new oral therapy, with high adoption intent among physicians and patients. Upcoming milestones include additional male and first female data releases.
Veradermics initiated with a Buy at Needham
Needham initiated coverage of Veradermics (MANE) with a Buy rating and $136 price target The company’s VDPHL01, a late-stage ER minoxidil product candidate, is well positioned to become the first…
Veradermics to Present at Upcoming June Investor Conferences
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for patt...
Veradermics Announces Poster Presentation on Topline Results from Phase 2/3 ‘302' Study of VDPHL01 at the 2026 World Congress for Hair Research
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for patt...
Veradermics price target raised to $135 from $120 at Citi
Citi raised the firm’s price target on Veradermics (MANE) to $135 from $120 and keeps a Buy rating on the shares. The firm updated the company’s model post the Q1…
Veradermics Announces Two Poster Presentations on VDPHL01 at the 2026 Music City SCALE Symposium
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for patt...
Veradermics Earnings release: Q1 2026
Veradermics released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Veradermics Quarterly report: Q1 2026
Veradermics has published its Q1 2026 quarterly earnings report on May 12, 2026.
Veradermics reports Q1 net income ($27.2M) vs ($12.4M) last year
Cash, cash equivalents, and marketable securities totaled $390.8 million as of March 31, 2026, reflecting net proceeds from the company’s upsized initial public offering completed in February 2026. Su...